Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15414500 | 0.84 | SLC2A1 (0.58) | SLC2A1HTTKMT2AMEN1KDM4E | |
| SCHEMBL28006237 | 0.80 | SLC2A1 (0.57) | SLC2A1HTTKDM4EXIAP | |
| SCHEMBL15413796 | 0.79 | MAPK1 (0.50) | L3MBTL1KMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL5077405 | 0.78 | SLC2A1 (0.51) | SLC2A1HTTKMT2AKDM4E | |
| SCHEMBL2130156 | 0.76 | HTT (0.56) | SLC2A1HTTKMT2AMEN1KDM4E | |
| SCHEMBL8876988 | 0.76 | NPC1 (0.57) | L3MBTL1HTTKMT2AMEN1KDM4E | |
| SCHEMBL15414672 | 0.75 | HPGD (0.56) | L3MBTL1KMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL4698919 | 0.75 | MAPT (0.58) | L3MBTL1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL28534417 | 0.75 | L3MBTL1 (0.52) | L3MBTL1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL15414421 | 0.74 | NPC1 (0.62) | SLC2A1L3MBTL1HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071562-B1 | TETRAHYDRO-BENZODIAZEPINONES | HOFFMANN LA ROCHE (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-10053431-B2 | Tetrahydro-benzodiazepinones | HOFFMANN-LA ROCHE INC. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2872490-B1 | ANTIPROLIFERATIVE BENZO[B]AZEPIN-2-ONES | HOFFMANN LA ROCHE (CH) | 2018-02-07 | — | — | EP | disclosed |
| US-9611224-B2 | Antiproliferative benzo [B] azepin-2-ones | HOFFMANN-LA ROCHE INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-3071562-A1 | TETRAHYDRO-BENZODIAZEPINONES | F. Hoffmann-La Roche AG (CH) | 2016-09-28 | — | — | EP | disclosed |
| US-20160272596-A1 | TETRAHYDRO-BENZODIAZEPINONES | HOFFMANN-LA ROCHE INC. | 2016-09-22 | — | — | US | disclosed |
| US-9394263-B2 | Substituted hetero-azepinones | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-9394263-B2 | Substituted hetero-azepinones | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150353499-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
| WO-2015071393-A1 | TETRAHYDRO-BENZODIAZEPINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-21 | — | — | WO | disclosed |
| EP-2872490-A1 | ANTIPROLIFERATIVE BENZO [B]AZEPIN- 2 - ONES | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| CN-104507913-A | Antiproliferative benzo[b]azepin-2-ones | HOFFMANN LA ROCHE | 2015-04-08 | — | — | CN | disclosed |
| WO-2014023708-A1 | SUBSTITUTED HETERO-AZEPINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014009495-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | CCNY, CCNE1, CCND3 | SLC2A1 3927/4885L3MBTL1 1802/4885HTT 1534/4885 |
| US-20150353499-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES | CCNY, RB1, TOP2B | SLC2A1 4478/4885L3MBTL1 1338/4885HTT 3879/4885 |
| US-10053431-B2 | Tetrahydro-benzodiazepinones | GABBR1, TPH1, GABBR2 | SLC2A1 4134/4885L3MBTL1 2441/4885HTT 2894/4885 |
| US-20160272596-A1 | TETRAHYDRO-BENZODIAZEPINONES | GABBR1, TPH1, GABBR2 | SLC2A1 4134/4885L3MBTL1 2441/4885HTT 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.